News und Analysen
LivaNova Reports First Quarter 2021 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021.
For the first quarter of 2021, worldwide
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
Regulatory News:
Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high
Chemed Reports First-Quarter 2021 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Verily, a subsidiary of Alphabet focused on life sciences and healthcare, today announced that the first
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.19 per share of Class A common stock issued and
Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced additional data at a late-breaking session at the American Academy of Dermatology VMX Experience. Etrasimod, a novel investigational drug
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial
QIAGEN gibt gemeinsam mit DiaSorin bekannt, den neuen Test LIAISON® LymeDetect® zur Frühdiagnose der Lyme-Borreliose in Ländern einzuführen, die das CE-Zeichen akzeptieren
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) und DiaSorin (FTSE MIB: DIA) haben heute die Einführung des TestsLIAISON® LymeDetect® in Ländern bekannt gegeben, die das CE-Zeichen
QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the launch of the LIAISON® LymeDetect® Assay for markets accepting the CE Mark, as an aid to
QIAGEN führt artus Prep&Amp als CE gekennzeichneten SARS-CoV-2-Test mit bis zu dreifacher täglicher Durchsatzerhöhung für PCR Labore ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung des artus® SARS-CoV-2 Prep&Amp UM Kits bekannt, das durch eine flüssigkeitsbasierte Probenvorbereitungstechnologie den
QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the artus® SARS-CoV-2 Prep&Amp UM Kit which uses a liquid based sample preparation technology to simplify and
LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for B-Capta®, the new
QIAGEN N.V. to Report First Quarter 2021 Results
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2021 on Monday, May 3, at approximately 22:05 Central
AMN Healthcare CSR Report Shows How AMN Fulfilled Its Social Responsibility in a Year of Unprecedented Challenges
AMN Healthcare (NYSE: AMN), the leader and innovator in healthcare workforce solutions and staffing services to healthcare facilities across the nation, released its 2020 Corporate Social
LivaNova Achieves Clinical Milestone in Heart Failure Program
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has randomized the 300th patient in the Autonomic Regulation Therapy to Enhance Myocardial
Charles River Laboratories Schedules First-Quarter 2021 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2021 financial results on Tuesday, May 4th, before the market opens. A conference call has been scheduled to
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR)
Community Healthcare System Partners with Premier, Inc. to Drive Operational Innovation and High-Quality Patient Care
Community Healthcare System, recognized for high-quality care across Northwest Indiana, has partnered with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company. Through this new
QIAGEN erweitert Test-Portfolio um Antigen-Schnelltests für den deutschen Markt
QIAGEN hat heute angekündigt, mehrere Millionen Antigen Schnelltests für Unternehmen in Deutschland ab sofort liefern zu können um die Wirtschaft bei ihrer Selbstverpflichtung zum Testen von
Chemed To Report First-Quarter 2021 Earnings April 27, Related Conference Call To Be Held On April 28
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the first quarter ended March 31, 2021, on Tuesday, April 27, 2021, following the close of trading on the
QIAGEN ergänzt COVID-19-Portfolio um neue, ultraschnelle Sequenzierungslösung für eine Genomüberwachung mit hohem Durchsatz
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung des QIAseq DIRECT SARS-CoV-2 Kit bekannt, einer Lösung zur Virusgenom-Anreicherung und Bibliotheksvorbereitung, mit
Premier, Inc. to Report Fiscal 2021 Third-Quarter Results and Host Conference Call on May 4, 2021
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2021 third quarter on Tuesday, May 4, 2021, at approximately 6:30 a.m. ET. The company will also
QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the launch of QIAseq DIRECT SARS-CoV-2 Kit, a viral genome enrichment and library preparation solution that significantly
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence’s artificial